Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Beatriz Honrubia-Peris"'
Autor:
Nuria Piera-Molons, Antonio Llombart-Cussac, Jose García-Sánchez, Beatriz Honrubia-Peris, Javier Garde-Noguera, Maria L. Fernández-Murga
Publikováno v:
Cancers
Cancers, Vol 13, Iss 4280, p 4280 (2021)
Cancers, Vol 13, Iss 4280, p 4280 (2021)
Simple Summary Immunotherapy, most notably immune checkpoint inhibitors (ICIs), has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Although some patients respond well to ICIs, many patients do not benefit from ICIs, lead
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4361ffae2ba94c7330dc4819c40448a7
https://pubmed.ncbi.nlm.nih.gov/34503087
https://pubmed.ncbi.nlm.nih.gov/34503087
Autor:
Jose Vidal-Martinez, J. Murado-Pardo, Ana Blasco, Silvia Calabuig-Fariñas, Javier Garde-Noguera, Sandra Gallach, Rafael Gisbert-Criado, Nuria Piera Molons, Jose Garcia Sanchez, Susana Torres Martinez, Beatriz Honrubia Peris, F. Zhang, Eloisa Jantus-Lewintre, Carlos Camps, Francisco Aparisi, Lauren Condori Farfan
Publikováno v:
Journal of Clinical Oncology. 37:e20685-e20685
e20685 Background: Immunotherapy with anti-PD1/PDL1 monoclonal antibodies has become the second line standard treatment for most patients diagnosed of advanced Non-Small-Cell lung cancer (NSCLC). The aim of this study is to assess the utility of circ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbd0c1b9addbe2eb1946a9b677adda88
https://doi.org/10.1200/jco.2019.37.15_suppl.e20685
https://doi.org/10.1200/jco.2019.37.15_suppl.e20685